The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
July 22nd 2025, 11:00pm
Bridging the Gaps in Lung Cancer
Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.
July 18th 2025, 9:25pm
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
July 18th 2025, 9:19pm
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
July 18th 2025, 7:02pm
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
July 18th 2025, 6:38pm
Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.
July 18th 2025, 5:57pm
Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
July 18th 2025, 3:05pm
Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.
July 18th 2025, 2:47pm
Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.
July 18th 2025, 2:24pm
Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.
July 17th 2025, 11:26pm
Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.
July 17th 2025, 11:15pm
Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.
July 17th 2025, 8:34pm
David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.
July 17th 2025, 8:33pm
Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.
July 11th 2025, 9:08pm
Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.
July 11th 2025, 7:31pm
Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.
July 7th 2025, 8:34pm
ESMO Gastrointestinal Cancers Congress
Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.
July 7th 2025, 8:15pm
ESMO Gastrointestinal Cancers Congress
Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.
July 7th 2025, 4:44pm
ESMO Gastrointestinal Cancers Congress
A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.
July 7th 2025, 4:26pm
ESMO Gastrointestinal Cancers Congress
Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.
July 6th 2025, 6:06pm
ESMO Gastrointestinal Cancers Congress
IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.